Background: Substantial improvements in survival have been observed in HER2 (human epidermal growth factor receptor 2)-positive (HER2+) inoperable or metastatic breast cancer (advanced breast cancer [ABC]) in recent years, driven by the introduction and widespread use of multiple novel agents. The DESTINY-Breast02 trial compared the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2+ AB...
Background: EGFR mutation is the most frequent in Non-Small Cell Lung Cancer and occurs mainly in women and non-smoking patients. Clinical case: We present the case of a 51-year-old female, former light smoker, diagnosed with lung adenocarcinoma in 2014, in stage IB. She underwent surgery and adjuvant therapy. She recurred after two years with metas-tatic lung and bone disease, with EGFR exon 21 mutation. Thera...
N/a.; N/a.
N/a.; N/a.